Capricor is approaching a regulatory filing timeline and earnings, while Sarepta heads into results under legal and safety pressure.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside?